(1) Company Name: FerroptoCure Inc.
(2) CEO: Yuji Otsuki
(3) Established: May 2022
(4) Capital: JPY 10,000,000
(5) Business Description: Drug discovery targeting ferroptosis
(6) Location:
Head Office:Fujimi Duplex B's 4F, 1-3-11 Fujimi, Chiyoda-ku, Tokyo MAP
Research Laboratory:Nano Medical Innovation Center (iCONM),
3-25-14 Tonomachi, Kawasaki-ku, Kawasaki city, Kanagawa MAP
FerroptoCure Australia Pty Ltd:Level 23, 68 Pitt Street, Sydney NSW 2000,
AustraliaModoras Accounting (SYD) Pty Ltd内） MAP
(7)Company History
Keio University Gene Regulation Research Division (Saya Lab)
Synthetic lethality by sulfasalazine and oxyfedrine
Foundation of FerroptoCure
Completed a seed funding round
Initiated a Phase 1 investigator-initiated clinical trial for FC-001
Initiation of developing FC004
Selected for the AMED Strengthening Program for Pharmaceutical Startup Ecosystem and completed a Series A funding round
Foundation of Australian subsidiary